BIOE on OTC
Bio Essence Corp
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with Decoy Therapeutics Inc., Lipocine Inc. or Oramed Pharmaceuticals, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Revenue From OEMServices brought in 100% of the revenue Bio Essence Corp broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2024 | 2025 |
|---|---|---|
| Revenue From OEMServices | $282.8K | $1.9M |
| Shipping And Delivery Income | $3.8K | $1.2K |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue25¢$469.2K
- Other costs28¢$531.4K
- Income tax0¢$800
- Profit47¢$896.2K
Out of $1.9M in revenue.3
Where each dollar of operating cash went, fiscal 2025
- Kept or used elsewhere100¢$1.6M
Out of $1.6M of cash from operations.3
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Total revenues | $1.9M | $323.9K |
| Total cost of revenues | $469.2K | $106.9K |
| Gross profit | $1.4M | $217.1K |
| Selling | $30.6K | |
| General and administrative | $497.8K | $676.5K |
| Total operating expenses | $528.4K | $676.5K |
| Income (loss) from operations | $900.0K | -$459.4K |
| Impairment loss of ROU asset | -$1.1M | |
| Interest expense | -$2.2K | -$2.2K |
| Other income | $701 | |
| Other expenses | -$828 | -$53.1K |
| Other expenses, net | -$3.0K | -$1.1M |
| Income (loss) before income tax | $897.0K | -$1.6M |
| Income tax expense | $800 | $800 |
| Net income (loss) from continuing operations | $896.2K | -$1.6M |
| Loss from discontinued operations | -$120.8K | |
| Gain from disposal of discontinued operations | $377.8K | |
| Net income (loss) | $896.2K | -$1.3M |
| Basic weighted average shares outstanding (in Shares) | 38.0M shares | 38.0M shares |
| Diluted weighted average shares outstanding (in Shares) | 38.0M shares | 38.0M shares |
| Basic net loss per share (in Dollars per share) | $0 | -$0 |
| Diluted net loss per share (in Dollars per share) | $0 | -$0 |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash | $1.4K | ||
| Accounts receivable | $23.5K | $5.1K | |
| Advances to vendors | $10.0K | $70.0K | |
| Prepaid expenses and other receivables | $3.8K | $202.2K | |
| Security deposits | $2.0K | ||
| Loan to shareholder | $385.2K | ||
| Total Current Assets | $422.4K | $280.7K | |
| Intangible assets, net | $97 | $332 | |
| Total Non-current Assets | $97 | $332 | |
| Total Assets | $422.5K | $281.0K | |
| Bank overdraft | $1.5K | ||
| Accounts payable | $47.9K | $17.7K | |
| Customer deposit | $848.6K | $187.1K | |
| Accrued liabilities and other payables | $35.9K | $338.1K | |
| Operating lease liabilities - current | $1.5M | $1.1M | |
| Government loans payable - current | $1.3K | $3.7K | |
| Loan from shareholders | $1.2M | ||
| Total Current Liabilities | $2.4M | $2.8M | |
| Operating lease liabilities - non-current | $392.3K | ||
| Government loans payable | $56.2K | $55.1K | |
| Total Non-current Liabilities | $56.2K | $447.4K | |
| Total Liabilities | $2.5M | $3.3M | |
| Common stock $0.0001 par value; authorized shares 100,000,000; issued and outstanding shares 38,009,000 | $3.8K | $3.8K | |
| Paid in capital | $7.5M | $7.5M | |
| Accumulated deficit | -$9.6M | -$10.4M | |
| Total Stockholders Deficit | -$2.1M | -$3.0M | -$1.7M |
| Total Liabilities and Stockholders Deficit | $422.5K | $281.0K | |
| Preferred stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Preferred stock, authorized shares (in Shares) | 10.0M shares | 10.0M shares | |
| Common stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Common stock, authorized shares (in Shares) | 100.0M shares | 100.0M shares | |
| Common stock, shares issued (in Shares) | 38.0M shares | 38.0M shares | |
| Common stock, shares outstanding (in Shares) | 38.0M shares | 38.0M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net income (loss) from continuing operations | $896.2K | -$1.3M |
| Depreciation and amortization expense | $235 | $911 |
| Loss on disposal of fixed assets | $3.0K | |
| Gain from disposal of discontinued operations | -$377.8K | |
| Operating lease expense | $41.9K | $452.6K |
| Impairment loss of ROU asset | $1.1M | |
| Accounts receivable | -$18.3K | -$5.1K |
| Receivable from sale of BEP | $700.0K | |
| Prepaid expenses and other receivables | $193.5K | -$197.3K |
| Prepayment and deposits | $66.9K | -$24.4K |
| Accounts payable | $30.1K | $5.3K |
| Customer deposit | $661.5K | $187.1K |
| Tax payable | -$244 | |
| Accrued interest | -$72 | |
| Accrued liability and other payables | -$302.0K | $200.4K |
| Payment of lease liability | -$47.1K | |
| Net cash provided by operating activities from continuing operations | $1.6M | $639.8K |
| Net cash used in operating activities from discontinued operations | -$16.0K | |
| Net cash provided by operating activities | $1.6M | $623.9K |
| Cash loss due to disposal of subsidiary | -$114 | |
| Net cash used in investing activities from continue operations | -$114 | |
| Net cash used in investing activities | -$114 | |
| Change in bank overdraft | $1.5K | -$9.4K |
| Loan from shareholder | $667.6K | |
| Repayment to shareholder | -$1.9M | -$602.5K |
| Loan to shareholder | -$485.2K | |
| Repayment from shareholder | $100.0K | |
| Repayment of SBA loan | -$1.3K | -$1.2K |
| Net cash used in financing activities from continuing operations | -$1.6M | -$613.2K |
| Net cash used in financing activities from discontinued operations | -$9.3K | |
| Net cash used in financing activities | -$1.6M | -$622.5K |
| NET INCREASE IN CASH | -$1.4K | $1.3K |
| Cash paid for interest | $2.2K | $6.3K |
| Cash paid for income taxes | $800 | $800 |
Recent filings
- Oct 14, 20264/A
- Oct 13, 2026144
- Aug 14, 202610-Q QUARTERLY REPORT
- May 19, 20268-K/A AMENDMENT NO. 1 TO FORM 8-K
- May 15, 202610-Q QUARTERLY REPORT
- Apr 24, 20268-K CURRENT REPORT
- Mar 27, 202610-K ANNUAL REPORT
- Jan 5, 2026QUALIF
- Nov 12, 202510-Q QUARTERLY REPORT
- Oct 17, 20251-A
- Aug 14, 202510-Q QUARTERLY REPORT
- May 15, 202510-Q QUARTERLY REPORT
- Mar 28, 202510-K ANNUAL REPORT
- Dec 5, 2024UPLOAD
- Nov 27, 202410-Q/A AMENDMENT NO. 3 TO FORM 10-Q
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9